Zydus Lifesciences Limited Financial Performance for Q4 & Full Year FY26

Zydus Lifesciences Limited has announced the Financial Performance for Q4 & Full Year FY26.Key Board Meetings Updates

- The audited results were taken on record by the Board of Directors at a meeting held today. The Board recommended a dividend of 100% for FY2025-26.

- The Board approved buyback of equity shares for an aggregate amount upto Rs. 11,000 mn, at a price of Rs. 1,150 per share (16% premium to closing price of 18th May 2026).

Q4 FY26 Highlights

- Revenue from operations at Rs. 75,870 mn, up 16% over last year.

- R&D investment s for the quarter stood at Rs. 6,982 mn (9.2% of revenues).

- EBITDA was Rs. 25,544 mn, up 20% y-o-y. EBITDA margin for the quarter stood at 33.7%, which is an improvement of 110 bps on a y-o-y basis.

- Net Profit (Adjusted) for the quarter was Rs. 15,929 mn, up 15% y-o-y.

- Capex (organic) for the quarter was Rs. 3,577 mn.

Full Year FY26 Highlights

- Revenue from operations at Rs. 2,71,484 mn, up 17% over last year.

- R&D investment s stood at Rs. 22,732 mn (8.4% of revenues).

- EBITDA was Rs. 84,751 mn, up 20% y-o-y. EBITDA margin stood at 31.2%, which is an improvement of 80 bps over the previous year.

- Net Profit (Adjusted) was Rs. 54,564 mn, up 15% y-o-y.

- Capex (organic) for the full year was Rs. 17,145 mn.

- Net Debt to Equity ratio as on 31st March 2026 was 0.16x while Net Debt to EBITDA stood at 0.5 0x at the end of March 2026.

"We closed FY26 on a strong note, delivering on our commitments - both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near-term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further." Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 1018.95 as compared to the previous close of Rs. 991.20. The total number of shares traded during the day was 390283 in over 17641 trades.

The stock hit an intraday high of Rs. 1048.45 and intraday low of 991.90. The net turnover during the day was Rs. 402643807.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate